The ALL Hub
is an open-access online resource dedicated to providing balanced, reliable, and up-to-date medical education in acute lymphoblastic leukemia (ALL) and will be launched today.
With the opening of our new hub, our aim is to enhance knowledge of ALL through the multichannel dissemination of global advances related to its classification, diagnosis, treatment, and management. To achieve this, the ALL Hub will share novel evidence-based articles, drug and trial updates, expert opinions, and disseminate international congress coverage to clinicians and scientists around the world.
Our vision is for every treatment team and researcher to have instant access to expert opinions and the latest evidence-based information in ALL, to aid in treatment decisions and improve the lives of patients with ALL globally. The mission of the ALL Hub is to enhance the collective knowledge base in ALL through global multichannel dissemination of the most up-to-date evidence-based information in ALL, to help inform on disease management and treatment strategies.
The ALL Hub has been founded in partnership with the European School of Haematology (ESH)
in 2021 and is guided by an international Steering Committee of experts in the field of ALL. The Steering Committee meets regularly to discuss the performance of the ALL Hub and devise action plans on how to best support the ALL community and address any unmet educational needs.
"In partnership with the European School of Haematology, the ALL Hub will contribute to the dissemination of knowledge and favor fruitful translational discussions in the field of ALL", Professor Hervé Dombret, Director, Institut Universitaire d’Hématologie (IUH), Université de Paris.
“The ALL Hub provides a unique resource to share cutting edge information about the biology and clinical approaches to improve outcomes for ALL, curated by experts”, Professor Charles Mullighan, Deputy Director, St. Jude Children’s Hospital.
“I am delighted to contribute to the ALL Hub which will offer fantastic opportunities for discussing with many other colleagues and experts in the field the most exciting novelties in the diagnosis and treatment of ALL”, Professor Franco Locatelli, Director, Department of Pediatric Hematology and Oncology, IRCCS Ospedale Pediatrico Bambino Gesù.
Professor Hervé Dombret joins the Steering Committee of the ALL Hub together with some of the worldwide experts in ALL and hematology-oncology research, including Charles Mullighan, Franco Locatelli, Elias Jabbour, Wendy Stock, Oliver Ottman, Sabina Chiaretti, Andrea Bondi, Mark Litzow, Nicola Gökbuget, Anita Rijneveld, André Baruchel, Jan Cools, Kjeld Schmiegelow, Helene Hallböök, José María Ribera, and Emmanuelle Clappier.
The ALL Hub owes thanks to the support of its founding industry partners, Novartis
(Silver) and Amgen
(Silver), without whom the platform would not be possible.
Scientific Education Support already has a portfolio of successful websites supporting the advancement of medical education in the field of hemato-oncology, which include the Lymphoma Hub, AML Hub, Multiple Myeloma Hub, GvHD Hub, MPN Hub, and MDS Hub.
For more information on the ALL Hub, please visit Lymphoblastic-hub.com
For media enquiries or to explore collaboration opportunities, please contact firstname.lastname@example.org
Press release distributed by Pressat on behalf of Scientific Education Support, on Wednesday 24 March, 2021. For more information subscribe and follow https://pressat.co.uk/